- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00457951
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD (COPD)
An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The management of acute exacerbations of COPD today is qualitatively the same as it was 40 years ago: bronchodilators, corticosteroids, and antibiotics. Because of the prominent pathophysiological role of neutrophils in exacerbations of COPD, neutrophils and their toxic oxidants and proteases represent therapeutic targets which are currently unchallenged in the treatment of this aspect of the disease. Ideally, to disrupt neutrophilic airway inflammation, one would both block neutrophilic influx from the vascular space into the airway, as well as neutralize or inactivate prominent neutrophilic toxins such as the proteases HLE and cathepsin G.
Heparin is a sulfated mucopolysaccharide that slows blood clot formation by inhibiting the reactions that lead to formation of fibrin clots. Physicians use heparin to prevent blood clot formation during open-heart surgery, bypass surgery and dialysis. Heparin also prevents previously formed clots from becoming larger and causing more serious problems. Heparin has other biological properties, most notably anti-inflammatory activity. At doses required to be therapeutically beneficial as an anti-inflammatory, heparin can cause severe, potentially life-threatening hemorrhage. ParinGenix has chemically modified heparin to retain the anti-inflammatory activity while reducing anti-coagulant properties.
Heparin has long been known to be a potent inhibitor, both in vitro and in vivo, of the cationic neutrophil proteases HLE and cathepsin G. However, heparin also has numerous other important anti-inflammatory effects. P-selectin is the primary endothelial attachment molecule mediating neutrophil rolling along the vessel wall. At concentrations close to those achieved in plasma near the high range of therapeutic anticoagulation, heparin inhibits P-selectin and P-selectin mediated interaction of leukocytes with endothelium. Heparin also blocks the leukocyte integrin Mac-1 (CD11b/CD18) and Mac-1-dependent leukocyte adherence to endothelial ICAM. These combined effects on rolling, integrin-dependent attachment and perhaps other aspects of cellular passage through the basement membrane prevent neutrophil accumulation in areas of inflammation. As an example, when given in much higher concentrations than those appropriate for therapeutic anticoagulation, heparin efficiently blocks neutrophilic influx into ischemic reperfused myocardium and brain reducing the size of both myocardial infarction and ischemic stroke. Thus, heparin and heparin analogues may have the potential to also reduce inflammatory influx of neutrophils into the airway during exacerbations of COPD.
All subjects will receive standard of care treatment, including corticosteroids, beta-2 agonists, and antibiotics as well as ODSH or placebo.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Leuven, Belgien, 3000
- University Hospital Gasthuisberg
-
Liege, Belgien, 4000
- CHU Liege Domain Universitaire du Sart Tilman
-
Yvior, Belgien, 5530
- Cliniques Universiaries U.C.L. de Mont-Gondinne
-
-
-
-
California
-
Orange, California, Förenta staterna, 92868
- Pulmonary Consultants & Primary Care
-
-
Georgia
-
Marietta, Georgia, Förenta staterna, 30060
- Wellstar Kennestone Hospital
-
-
Louisiana
-
Shreveport, Louisiana, Förenta staterna, 71130
- Louisiana State University Health Sciences Center in Shreveport
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington Universtiy school of Medicine
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97220
- The Oregon Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19140
- Temple University of the Commonwealth of Higher Education
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Michael E. DeBakey VA Medical Center
-
Houston, Texas, Förenta staterna, 77030
- Methodist Hospital
-
Tyler, Texas, Förenta staterna, 75708
- University of Texas Health Care Center at Tyler
-
-
Washington
-
Everett, Washington, Förenta staterna, 98201
- Western Washington Medical Group
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 1T2
- Kelowna General Hospital
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Vancouver Coastal Health
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
- St. Boniface General Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- QE II Health Sciences Centre
-
-
Ontario
-
Mississauga, Ontario, Kanada
- Credit Valley Hospital,
-
Ottawa, Ontario, Kanada, K1Y 4E9
- The Ottawa Hospital, Civic Campus
-
Toronto, Ontario, Kanada, H2X-2P4
- University of Toronto
-
-
Quebec
-
Quebec City, Quebec, Kanada, G1V 4G5
- Laval Hospital
-
-
-
-
-
Czestochowa, Polen, 42-200
- Wojewodzki Szpital Specjalistyczny im. Najswietszej Marii Panny
-
Katowice, Polen, 40-752
- Samodzielny Publiczny Szpital Kliniczny SUM w Katowicach
-
Krakow, Polen, 31-202
- Krakowski Szpital Specjalistyczny im. Jana Pawla II
-
Lodz, Polen, 90-153
- Samodzielny Publiczny ZOZ, Uniwersytecki Szpital Liniczny nr 1 im Norberta Barlickiego
-
Lublin, Polen, 20-718
- Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego, Samodzielny Publiczny Zespol Opieki Zdrowotnej
-
Lublin, Polen, 20-954
- Samodzielny Publiczny Szpital Klinczny nr 4 W Lublinie
-
Olawa, Polen, 55-200
- Zespol Opieki Zdrowotnej w Olawie
-
Poznan, Polen, 60-569
- Wieklopolskie Centrum Chorob Pluc i Gruzlicy
-
Warszawa, Polen, 04-749
- Miedzyleski Szpital Specjalistyczny w Warszawie
-
Warszawa, Polen, 01-138
- I Klinika Chorob Plus, Instyut Gruzlicy i Chorob Pluc
-
Wroclaw, Polen, 50-417
- Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego
-
-
-
-
-
Gerlingen, Tyskland, 70839
- Klinik Schillerhohe
-
Grosshansdorf, Tyskland, 22927
- Pneumologisches Forschungsinstitut GmbH
-
Hannover, Tyskland, 30625
- Medizinsche Hochschule
-
Mainz, Tyskland, 55101
- Uniklinikum Mainz
-
Munchen, Tyskland, 80336
- Klinikum der LMU Innenstadt
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female patients (40 years of age or older) with an established diagnosis of COPD based upon medical history who are being admitted to the hospital to treat an exacerbation of COPD;
- Normal prothrombin time and activated partial thromboplastin time; Platelet count; hemoglobin and hematocrit
Exclusion Criteria:
Certain diseases such as:
- asthma;
- left heart failure or pulmonary embolism;
- lung cancer;
- pneumonia
- liver or kidney disease
- blood clotting disorder
- Positive HIV or hepatitis tests
- GI bleeding, physical trauma with bleeding, any disease with bleeding within 60 days of study entry
Certain medications such as:
- Plavix®
- Warfarin
- Heparin therapy
- Certain antibiotics
- Exacerbations that are too severe (requiring intubation and mechanical ventilation)
- Women of child-bearing potential, pregnancy or breast-feeding
- Unable or unwilling to provide informed consent and follow study procedures.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Open Label
Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
|
ODSH administered open-label
Andra namn:
|
Placebo-jämförare: 0.9% Sodium Chloride
Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
|
Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
Andra namn:
|
Aktiv komparator: Randomized, Blinded, ODSH Arm
Subjects will receive standard of care treatment.
ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo.
The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
|
Randomized, Blinded, ODSH Arm
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of Treatment Failure
Tidsram: Time to hospital discharge and 21 days post-treatment, up to 31 days
|
The primary outcome of the study is "Treatment Failure" as defined by Failure to discharge from hospital based on GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease) criteria or relapse after DC from hospital.
|
Time to hospital discharge and 21 days post-treatment, up to 31 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Tobias Welte, MD, Hannover Medical School
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PGX-ODSH-2006
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Open-Label
-
Massachusetts General HospitalNational Center for Complementary and Integrative Health (NCCIH); Harvard...AvslutadMajor depressiv sjukdomFörenta staterna
-
Scion NeuroStimAnmälan via inbjudanParkinsons sjukdom | Parkinsons sjukdom och ParkinsonismFörenta staterna
-
AI Therapeutics, Inc.AvslutadAkut myeloid leukemi | OnkologiFörenta staterna
-
Universitätsklinikum Hamburg-EppendorfAvslutad
-
University of California, San FranciscoRekrytering
-
Studio Osteopatico Busto ArsizioRekrytering
-
Krystal Biotech, Inc.AvslutadDystrofisk epidermolys Bullosa | Recessiv dystrofisk epidermolys Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis BullosaFörenta staterna
-
University of California, Los AngelesAnmälan via inbjudan
-
ES Therapeutics Australia Pty LtdRekryteringLäkemedelsresistent epilepsiAustralien
-
Protagonist Therapeutics, Inc.Anmälan via inbjudanPolycytemi VeraFörenta staterna